News & Updates

ACOG article 2.3

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

Breastfeeding delivers long-term cardiometabolic benefits in offspring

In a secondary analysis of the HAPO FUS*, breastfeeding was found to be associated with lower rate of glucose metabolism disorders in the offspring; however, this association was not seen among the mothers.

Higher aspirin dose may attenuate severe pre-eclampsia risk among high-risk women with obesity

Doubling the routine aspirin dose used for pre-eclampsia prevention appears to help lower the risk of developing pre-eclampsia with severe features among high-risk pregnant women with obesity, according to the results of the open-label ASPREO trial.

Maternal transplacental transfer of nipocalimab negligible in foetuses, neonates

In the phase II UNITY study, foetuses and neonates whose mums were receiving nipocalimab for early-onset (≤24 weeks gestational age [GA]) severe haemolytic disease of the foetus and newborn (EOS-HDFN) had minimal exposure to the drug.

ACOG article 2.4

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

Original New Drug Application Approvals by US FDA (1-15 March 2024)

ACOG article 2.6

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

ACOG article 2.1

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.

ACOG article 2.7

Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.